首页> 中国专利> 胆酸派生物及其在制备预防或治疗FXR介导的疾病或状况的药物中的应用

胆酸派生物及其在制备预防或治疗FXR介导的疾病或状况的药物中的应用

页面导航

摘要
著录项
法律信息
相似文献

摘要

本发明涉及结构(I)的化合物：其中R是氢或α-羟基；位置7上的羟基基团是α或β位；和药学上可接受的盐，溶剂化物或其氨基酸结合物。

著录项

公开/公告号CN101522703B

专利类型发明专利
公开/公告日2013-04-17

原文格式PDF
申请/专利权人英特塞普特医药品公司;
展开▼

申请/专利号CN200780032111.9
发明设计人 R·佩里恰里;S·菲奥鲁西;M·普鲁泽斯基;
展开▼

申请日2007-06-27
分类号C07J9/00(20060101);A61K31/575(20060101);
代理机构72001 中国专利代理(香港)有限公司;
代理人万雪松;李进
地址美国纽约州
入库时间 2022-08-23 09:14:00

法律信息

法律状态公告日

法律状态信息

法律状态
2013-04-17

授权

授权
2009-10-28

实质审查的生效

实质审查的生效
2009-09-02

公开

公开

相似文献

专利
中文文献
外文文献

1. 胆酸派生物及其在制备预防或治疗FXR介导的疾病或状况的药物中的应用 [P] . 中国专利： CN101522703B . 2013.04.17
2. 细格菌素类化合物及其药学上可接受的盐在制备治疗FXR介导疾病药物中的应用 [P] . 中国专利： CN103054843B . 2015.04.22
3. Immunoconjugate, methods for treating multiple myeloma in an individual, for dispensing immunoconjugate-mediated drug, for inhibiting, delaying and / or preventing tumor development and / or dispensing malignant tumor cells in a patient in need thereof, for treating an individual having a condition and to decrease the amount of cells in direct or indirect contact with immunoconjugates, a method for treating multiple myeloma in an individual, to dispense immunoconjugate-mediated medication, to inhibit, delay and / or prevent tumor cell development in a cell culture, to inhibit, delay and / or prevent the development of a tumor and / or dispense malignant tumor cells in a patient in need thereof, to treat an individual having a condition and to decrease a number of cells in direct or indirect contact. with tumor cells, pharmaceutical composition, and kit. [P] . BRPI0821449A2 . 2015-06-16

机译：免疫缀合物，用于在个体中治疗多发性骨髓瘤的方法，用于分配免疫缀合物介导的药物，用于在需要其的患者中抑制，延迟和/或预防肿瘤的发展和/或分配恶性肿瘤细胞，用于治疗患有以下疾病的个体：为了减少与免疫缀合物直接或间接接触的细胞数量，一种用于治疗个体多发性骨髓瘤，分配免疫缀合物介导的药物，抑制，延迟和/或预防细胞培养中肿瘤细胞发展，抑制，在有需要的患者中延迟和/或预防肿瘤的发展和/或分配恶性肿瘤细胞，以治疗患有某种疾病的个体并减少直接或间接接触的细胞数量。带有肿瘤细胞，药物成分和试剂盒。
4. Methods of reducing the possibility of mortality in an animal, virulent expression in an intestinal pathogen, and adhesin / lectin pa-i expression in a bacterial cell, inhibiting adhesin / lectin pa-i expression in an intestinal pathogen, intestine-induced activation of adhesin / lectin pa-i, c4-hsl-induced morphological change of an intestinal pathogen, and bacterial cell adhesion in a mammalian intestine, improvement of intestinal pathogenesis, disease prevention or abnormal condition, skin and respiratory infection, sexually transmitted disease, digestive tract disorder, loss of lactating capacity in an animal, and development of a microbe-mediated epithelial disorder in a nursing-age animal, irrigation of at least a portion of the urinary tract, and for monitoring the administration of poly (ethylene glycol) (peg) to an animal, composition pharmaceuticals, kits for the prevention or therapeutic treatment of bowel-derived sepsis, and for monitoring the administration of poly (ethyle [P] . BR0215954A . 2005-09-13

机译：减少动物死亡，肠道病原体中强毒表达以及细菌细胞中粘附素/凝集素pa-i表达，抑制肠道病原体中粘附素/凝集素pa-i表达，肠道诱导的粘附素活化的方法/凝集素pa-i，c4-hsl诱导的肠道病原体形态变化和哺乳动物肠道细菌细胞粘附，改善肠道发病机制，预防疾病或异常状况，皮肤和呼吸道感染，性传播疾病，消化道疾病，动物泌乳能力的丧失以及哺乳期动物中微生物介导的上皮疾病的发展，至少一部分尿路的冲洗以及用于监测聚乙二醇（peg）的给药动物，组合物药物，用于预防或治疗肠源性败血症并监测多乙
5. Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions [P] . 美国专利： US9763964B2 . 2017-09-19

机译：胆汁酸衍生物作为FXR配体，用于预防或治疗FXR介导的疾病或状况